Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

OBJECTIVES: To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in RAPID-PsA (NCT01087788), an ongoing Phase 3 trial in patients with psoriatic arthritis (PsA). METHODS: Patients were randomised 1:1:1 to placebo, 200 mg CZP every 2 weeks (Q2W) or 400 mg CZP every 4 weeks (...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Mease, P J, Fleischmann, R, Deodhar, A A, Wollenhaupt, J, Khraishi, M, Kielar, D, Woltering, F, Stach, C, Hoepken, B, Arledge, T, van der Heijde, D
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2014
Aiheet:
Clinical and Epidemiological Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3888622/
https://ncbi.nlm.nih.gov/pubmed/23942868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2013-203696
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia